Amoxycillin 250 mg + Cloxacillin 250 mg + Lactic Acid Bacillus 1.7 Million Spores
This triple-component capsule combines two mechanistically distinct penicillins with a probiotic, creating a formulation with both gram-positive and beta-lactamase-resistant staphylococcal coverage alongside gut protection.
Amoxycillin (250mg) is a broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding PBPs, providing coverage against gram-positive streptococci, gram-negative H. influenzae, and enterococci. Cloxacillin (250mg) is a beta-lactamase-stable isoxazolyl penicillin specifically designed to resist staphylococcal beta-lactamase enzymes. It binds PBP2a with high affinity, making it the oral agent of choice against methicillin-sensitive Staphylococcus aureus (MSSA). The combination of these two penicillins provides complementary coverage — amoxycillin covering streptococcal and gram-negative organisms while cloxacillin handles MSSA, together covering the full polymicrobial spectrum of skin, ENT, and soft tissue infections.
Lactic Acid Bacillus (1.7 million spores) restores and maintains gut flora integrity during dual antibiotic therapy, significantly reducing antibiotic-associated diarrhoea and improving treatment completion.
Skin and Soft Tissue Infections: Primary indication. Cellulitis, impetigo, furunculosis, carbuncles, infected eczema, and wound infections where both Staphylococcus aureus and Streptococcus pyogenes are implicated. The cloxacillin component specifically addresses MSSA, the most common pathogen in skin infections, while amoxycillin covers streptococcal co-infection.
ENT Infections: Otitis externa, peritonsillar abscess, parotitis, and submandibular space infections with polymicrobial staphylococcal/streptococcal aetiology.
Paediatric Infections: Impetigo, infected insect bites, omphalitis, and superficial skin infections in children where staphylococcal organisms predominate.
Post-Surgical Infections: Mild to moderate superficial wound infections following ENT, dental, or minor skin procedures.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Skin and soft tissue infections are among the most common presentations in general practice and dermatology OPDs across India. The challenge: most involve either Staphylococcus aureus or Streptococcus pyogenes — or both. Plain amoxycillin covers streptococci well but misses MSSA; cloxacillin covers MSSA but has limited streptococcal activity. The combination in STRIKEMOX™ CX LB addresses this clinical reality by providing full polymicrobial cover in a single capsule.
The addition of Lactic Acid Bacillus is particularly thoughtful — patients on three to four times daily penicillin therapy for skin infections frequently discontinue early due to gastrointestinal side effects. LB directly reduces this dropout risk. For dermatologists and general practitioners building prescribing patterns around reliable, well-tolerated agents, this combination represents a clinically rational choice backed by Seclis Labs' WHO-GMP manufacturing quality.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.